Genetic risk score tracked melanoma cases in older ASPREE trial group
Bakshi and colleagues tested a 55-variant polygenic risk score for cutaneous melanoma in 12,712 participants of the ASPirin in Reducing Events in the Elderly trial. Mean age at baseline was 75. Over a median follow-up of 4.7 years, the score was associated with incident melanoma (hazard ratio 1.46 per standard deviation) and with prevalent melanoma (odds ratio 1.55 per standard deviation). Participants in the highest-risk group had roughly two to four times the odds of melanoma compared with those in the lowest-risk group.
The score tracked melanoma risk in this older group and may help identify who needs closer skin surveillance.
Source: Genomic Risk Score for Melanoma in a Prospective Study of Older Individuals. (doi.org).
Written by the Genomes desk from the primary source linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].
- UK Biobank expands genetic analysis to diverse ancestry groups September 18, 2025
- FinnGen study finds 30 new disease associations in Finnish population January 18, 2023
- GWAS Catalog adds sequencing data, links to Polygenic Score Catalog January 1, 2023
- Common gene variants change how a rare cleft palate mutation plays out July 1, 2022
- Polygenic scores lose accuracy fast across UK Biobank ancestry groups January 1, 2022